The global anti-inflammatory drugs market size was estimated to be USD 114.62 billion in 2023 and is expected to reach at USD 341.02 billion by 2034 with a CAGR of 10.42% during the forecast period 2024-2034. Rising prevalence of chronic conditions such as Asthma, Arthritis, & Chronic obstructive pulmonary disease (COPD), increasing advancements in Anti Inflammatory Biologics & Immune Selective Anti-Inflammatory Derivatives (ImSAIDs), growing awareness regarding anti-inflammatory therapeutics, surge in government initiatives, rising demand for OTC NSAIDs, increasing product approvals, growing introduction of combination drugs, and surge in launch of new products are some of the key factors boosting the market growth.
Surge in launch of new products is predicted to boost the market growth during the forecast period. Biologic medications possess immunosuppressive properties and aim to address components of the immune system responsible for triggering inflammation. Due to rising demand and a smoother approval process in comparison to novel drugs, numerous manufacturers have redirected their efforts towards creating biosimilar versions. Non-steroidal anti-inflammatory drugs (NSAIDs) are the primary choice for managing pain and inflammation. For instance, in August 2022, Haleon has introduced Advil Plus Acetaminophen, a product that blends ibuprofen and acetaminophen to provide dual pain relief. This marks a significant offering from Haleon, which emerged as a standalone company dedicated solely to consumer healthcare.
By drug class, biologics was the highest revenue-grossing segment in the global anti-inflammatory drugs market in 2023 owing to rising number of patient population suffering from chronic disease & lack of effective treatments, growing healthcare spending, and increasing awareness regarding biologics. Additionally, nonsteroidal anti-inflammatory diseases (NSAIDs) is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption of over-the-counter non-steroidal anti-inflammatory drugs and growing launch of new products. For instance, in May 2022, Dr. Reddy's Laboratories has introduced Ketorolac Tromethamine tablets USP, 10 mg, to the market in the United States. These tablets, at a strength of 10 mg, are a non-steroidal anti-inflammatory medication prescribed for the temporary treatment of moderately intense acute pain.
By indication, arthritis was the highest revenue-grossing segment in the global anti-inflammatory drugs market in 2023 owing to increasing prevalence of arthritis & osteoarthritis, growing geriatric population, rising adoption of topical preparations for subsiding arthritis, and surge in regulatory approvals of novel products. For instance, in June 2022, Amgen has reported the approval by the U.S. Food and Drug Administration (FDA) for RIABNI (rituximab-arrx), a biosimilar to Rituxan. This approval is for the usage of RIABNI, combined with methotrexate, to treat adults experiencing moderate to severely active rheumatoid arthritis (RA) who have not responded sufficiently to one or more tumor necrosis factor (TNF) antagonist therapies. Additionally, migraine is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of migraine and surge in approvals of advanced formulations.
By route of administration, oral was the highest revenue-grossing segment in the global anti-inflammatory drugs market in 2023 owing to higher availability of oral products, rising research & development activities, and growing adoption of new drug delivery systems. Additionally, topical is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of topical NSAID medications, rising demand for topical drugs, and increasing launch of advanced medications. For instance, in August 2022, The USPTO has granted a Notice of Allowance for a patent application filed by Baudax Bio, Inc., titled 'Approaches to administering meloxicam intravenously in a single dose.' This patent includes assertions related to utilizing several administrations of ANJESO to address moderate to severe pain, resulting in a reduction in cumulative effects.
By distribution channel, retail pharmacy was the highest revenue-grossing segment in the global anti-inflammatory drugs market in 2023 owing to surge in number of AIDs prescriptions for pain management, rising launch of innovative drugs by market players, and increasing mergers & acquisitions within market players. For instance, in March 2022, Pfizer Inc has completed the acquisition of Arena Pharmaceuticals, a move that empowers the company to expand and improve its range of products in the fields of gastroenterology, dermatology, and cardiology. This strategic purchase bolsters the company's capabilities and knowledge in the area of inflammation and immunology, offering complementary strengths. Additionally, hospital pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption anti-inflammatory drugs for pain management in hospitalized patients and growing regulatory approvals of new products.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing strategic initiatives undertaken by market players, rising prevalence of chronic diseases, increasing approvals by regulatory bodies. For instance, in May 2023, AbbVie Inc has obtained approval from the U.S. Food and Drug Administration (FDA) for RINVOQ (upadacitinib) in treating adults dealing with moderately to severely active Crohn's disease. This approval is anticipated to strengthen the company's portfolio in the realm of anti-inflammatory medications and propel revenue growth. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing geriatric population, increasing prevalence of chronic pain, migraine, & headaches, surge in product approvals, and rising approvals of innovative products by regulatory authorities. For instance, in August 2022, Strides Pharma Global Pvt Ltd has been granted approval by the U.S. health regulatory authority for their generic naproxen sodium soft gel capsules, which are employed in the management of pain and inflammation.
Surge in launch of new products is predicted to boost the market growth during the forecast period. Biologic medications possess immunosuppressive properties and aim to address components of the immune system responsible for triggering inflammation. Due to rising demand and a smoother approval process in comparison to novel drugs, numerous manufacturers have redirected their efforts towards creating biosimilar versions. Non-steroidal anti-inflammatory drugs (NSAIDs) are the primary choice for managing pain and inflammation. For instance, in August 2022, Haleon has introduced Advil Plus Acetaminophen, a product that blends ibuprofen and acetaminophen to provide dual pain relief. This marks a significant offering from Haleon, which emerged as a standalone company dedicated solely to consumer healthcare.
By drug class, biologics was the highest revenue-grossing segment in the global anti-inflammatory drugs market in 2023 owing to rising number of patient population suffering from chronic disease & lack of effective treatments, growing healthcare spending, and increasing awareness regarding biologics. Additionally, nonsteroidal anti-inflammatory diseases (NSAIDs) is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption of over-the-counter non-steroidal anti-inflammatory drugs and growing launch of new products. For instance, in May 2022, Dr. Reddy's Laboratories has introduced Ketorolac Tromethamine tablets USP, 10 mg, to the market in the United States. These tablets, at a strength of 10 mg, are a non-steroidal anti-inflammatory medication prescribed for the temporary treatment of moderately intense acute pain.
By indication, arthritis was the highest revenue-grossing segment in the global anti-inflammatory drugs market in 2023 owing to increasing prevalence of arthritis & osteoarthritis, growing geriatric population, rising adoption of topical preparations for subsiding arthritis, and surge in regulatory approvals of novel products. For instance, in June 2022, Amgen has reported the approval by the U.S. Food and Drug Administration (FDA) for RIABNI (rituximab-arrx), a biosimilar to Rituxan. This approval is for the usage of RIABNI, combined with methotrexate, to treat adults experiencing moderate to severely active rheumatoid arthritis (RA) who have not responded sufficiently to one or more tumor necrosis factor (TNF) antagonist therapies. Additionally, migraine is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of migraine and surge in approvals of advanced formulations.
By route of administration, oral was the highest revenue-grossing segment in the global anti-inflammatory drugs market in 2023 owing to higher availability of oral products, rising research & development activities, and growing adoption of new drug delivery systems. Additionally, topical is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of topical NSAID medications, rising demand for topical drugs, and increasing launch of advanced medications. For instance, in August 2022, The USPTO has granted a Notice of Allowance for a patent application filed by Baudax Bio, Inc., titled 'Approaches to administering meloxicam intravenously in a single dose.' This patent includes assertions related to utilizing several administrations of ANJESO to address moderate to severe pain, resulting in a reduction in cumulative effects.
By distribution channel, retail pharmacy was the highest revenue-grossing segment in the global anti-inflammatory drugs market in 2023 owing to surge in number of AIDs prescriptions for pain management, rising launch of innovative drugs by market players, and increasing mergers & acquisitions within market players. For instance, in March 2022, Pfizer Inc has completed the acquisition of Arena Pharmaceuticals, a move that empowers the company to expand and improve its range of products in the fields of gastroenterology, dermatology, and cardiology. This strategic purchase bolsters the company's capabilities and knowledge in the area of inflammation and immunology, offering complementary strengths. Additionally, hospital pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption anti-inflammatory drugs for pain management in hospitalized patients and growing regulatory approvals of new products.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing strategic initiatives undertaken by market players, rising prevalence of chronic diseases, increasing approvals by regulatory bodies. For instance, in May 2023, AbbVie Inc has obtained approval from the U.S. Food and Drug Administration (FDA) for RINVOQ (upadacitinib) in treating adults dealing with moderately to severely active Crohn's disease. This approval is anticipated to strengthen the company's portfolio in the realm of anti-inflammatory medications and propel revenue growth. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing geriatric population, increasing prevalence of chronic pain, migraine, & headaches, surge in product approvals, and rising approvals of innovative products by regulatory authorities. For instance, in August 2022, Strides Pharma Global Pvt Ltd has been granted approval by the U.S. health regulatory authority for their generic naproxen sodium soft gel capsules, which are employed in the management of pain and inflammation.
Segmentation: Anti-Inflammatory Drugs Market Report 2022 - 2033
Anti-Inflammatory Drugs Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)
- Corticosteroids
- Biologics
- Nonsteroidal Anti-inflammatory Diseases (NSAIDs)
Anti-Inflammatory Drugs Market Analysis & Forecast by Indication 2023 - 2034 (Revenue USD Bn)
- Ophthalmic Diseases
- Migraine
- Arthritis
- Others
Anti-Inflammatory Drugs Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Topical
- Oral
- Others
Anti-Inflammatory Drugs Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Online Pharmacy
- Hospital Pharmacy
- Retail Pharmacy
Anti-Inflammatory Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Anti-Inflammatory Drugs Market: Drug Class Estimates & Trend Analysis
8. Anti-Inflammatory Drugs Market: Indication Estimates & Trend Analysis
9. Anti-Inflammatory Drugs Market: Route of Administration Estimates & Trend Analysis
10. Anti-Inflammatory Drugs Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Anti-Inflammatory Drugs Market
13. Europe Global Anti-Inflammatory Drugs Market
14. Asia Pacific Global Anti-Inflammatory Drugs Market
15. Latin America Global Anti-Inflammatory Drugs Market
16. MEA Global Anti-Inflammatory Drugs Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Novartis AG
- Amgen Inc
- F. Hoffmann-La Roche AG
- Johnson & Johnson
- PFIZER INC.
- Merck & Co. Inc.
- Eli Lily And Company
- Glaxosmithkline Plc
- Astrazeneca PLC.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 114.62 Billion |
| Forecasted Market Value ( USD | $ 341.02 Billion |
| Compound Annual Growth Rate | 10.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
